对儿童X线体检中减少照射剂量的探讨

目的:探讨儿童在X线体检中减少照射剂量的方法。方法:应用东芝500mA遥控X线机、FJ-427型热释光剂量仪等设备,对100名3~5岁儿童体检时,随机分成两个对照组、每组50名,分别接受胸透或平片检查,对检查测得数据均进行统计学处理。结果:胸透时胸部接受的照射剂量是平片的22倍多,其它部位接受的X线散射剂量平均值之比亦在20~30倍之间。结论:在儿童X线体检中应采用常规胸片替代胸透,可以有效地降低其辐射危害。     

SOD药膜预防治疗急性放射性口腔炎的临床观察

目的　探讨超氧化物歧化酶 (SOD)对急性放射性口腔炎的临床价值。方法　 90例首程放疗鼻咽癌病人随机分为 3组 :A组用自制的SOD药膜 ;B组用维斯克药液 ;C组不行任何治疗。所有病人均于第 2周末开始观察、用药 ,直至放疗第 6周末。结果　A组放射性口腔炎的发病率明显低于C组 (P <0 0 5 ) ;A组放射性口腔炎的有效率明显高于C组 (P <0 0 1)。结论　SOD对急性放射性口腔炎有明显预防及治疗作用。     

广东省放射工作人员健康状况调查

目的　了解长期小剂量电离辐射对放射工作人员健康的影响 ,为保障其工作者的健康和改进防护措施提供依据。方法　通过职业流行病学现况调查的方法 ,按照广东省放射工作人员职业健康体检规范要求 ,对 2 0 0 2年广东省999例放射工作人员的职业健康状况进行分析。结果　随着工龄增加 ,放射工作人员眼科检查的异常率增加。血液常规检查和细胞遗传学指标 (外周血淋巴细胞微核率 )及眼晶状体混浊率 ,部分组间指标差异有统计学意义。男性微核率的异常率 >15年组是 <5年组的 5 2倍 ,是 5～ 15年组的 1 4倍 ,女性微核率异常率 >15年组是 <5年组的 3 3倍 ,是 5～15年组的 2 5倍。结论　加强放射卫生监督管理 ,重点保护暴露工龄较长的放射工作人员 ,以减低放射对该人群的影响     

中药复方对辐射损伤小鼠脾细胞凋亡及mRNA表达的影响

目的探讨中药复方地甘口服液(DGOL)对辐射损伤小鼠脾细胞凋亡及凋亡相关基因bcl-2和bax mRNA表达的作用.方法建立辐射损伤模型(一次性7.0Gy的X射线照射),喂饲100%地甘口服液每次0.2 ml/10 g小鼠,每日2次.第10天用原位末端标记的TUNEL技术检测脾组织细胞凋亡和原位杂交法检测凋亡相关基因bcl-2和bax mRNA的表达.结果地甘口服液组与对照组比脾脏的细胞凋亡率和bax mRNA表达显著减少(P＜0.01),bcl-2 mRNA的表达显著增强(P＜0.01).结论中药复方地甘口服液可能通过促进bcl-2和降低bax mRNA的表达,促进造血细胞的增生,提高机体免疫力.     

Radiation doses deriving from patients undergoing 111In-DTPA-d-Phe-1-octreotide scintigraphy

The purpose of this study was to estimate the radiation doses to nursing staff, other patients, accompanying persons and family members deriving from patients undergoing ¹¹¹In-DTPA-d-Phe-1-octreotide (¹¹¹In-OCT) scintigraphy. Dose rates were measured from 16 patients who had received an intravenous injection of 140±40 MBq ¹¹¹In-OCT. The measurements were performed at three different distances (0.5, 1 and 2 m) at 10–20 min, 5–7 h and 24 h (and in some cases, up to 48 h) after administration of ¹¹¹In-OCT. The effective half-lives of the biexponential decrease of the dose rates were estimated to be 2.94±0.27 h (T ₁) and 65.17±0.58 h (T ₂). The calculated maximum dose to other persons in the waiting area was 27.2 μSv, to family members 61.5 μSv, to nursing staff in a ward 24.1 μSv and to neighbouring patients in the ward 69.5 μSv. Our results clearly demonstrate that the calculated maximum radiation exposure to accompanying persons, personnel, family members and other patients is well below the maximum annual dose limit for non-professionally exposed persons. Received 20 May and in revised form 9 July 1997     

放射治疗在脊柱骨巨细胞瘤治疗中的价值

作者回顾性评价放射治疗在脊柱骨巨细胞瘤（ＧＣＴ）治疗中的价值。本组１０例（男６例，女４例），年龄１８～３４岁（平均２７岁）。发病部位：颈椎６例，胸腰椎２例，腰、骶椎各１例。Ｊａｆｅ分级：Ⅰ级３例，Ⅰ－Ⅱ级２例，Ⅱ级１例，Ⅲ级２例，未分级２例。治疗方法：（１）单纯放疗治疗颈椎ＧＣＴ３例。（２）先放疗后手术治疗胸腰段ＧＣＴ２例。（３）先手术后放疗治疗颈椎ＧＣＴ３例，腰椎ＧＣＴ１例。（４）手术配合术前与术后放疗治疗骶椎ＧＣＴ１例。随访１．５～２９年（平均１４年）均无复发。５例生活自理，４例恢复工作，１例恢复较差。本组无放疗后恶变。作者认为，脊柱解剖复杂，难以将肿瘤彻底切除，所以手术配合术前术后放疗对脊柱ＧＣＴ的治疗有重要意义。     

周围剂量当量仪的研制

周围剂量当量仪研制是根据国际辐射单位和测量委员会（ＩＣＲＵ）３９号报告推荐的周围剂量当量而设计的一种数字化智能型辐射防护仪。方法采用能量补偿对探测器进行能响校正。结果补偿结果使得探测器在４７～２３０ｋｅＶ与ＩＳＯ推荐的Ｈ＊（１０）／Ｋａ值误差在５％以内。本文重点描述了周围剂量当量仪探测器部分的工艺结构和剂量学性能以及电子学测量部分的主要功能。结论通过实际应用我们初步获得的结论是由于该仪器可直接测量周围剂量当量，稳定性好且具有自动取平均值特点，它可做为实验室校准用测量仪器，又由于该仪器体积小，电池供电，读数面板又有背光功能，它也可以做为现场仪器用于辐射防护实践的现场测量     

肺结核线索调查中X线胸透的代价和效益试评

用热释光剂量计测试了受检者胸透体表照射量，结果表明受检者体表照射量符合对数正态分布，几何均值为０．１９ｍＣ·ｋｇ－１，高于一般体检胸透照射量水平。根据危险度系数，估算出由此造成的辐射诱发恶性肿瘤危险度，男女分别为３．５５×１０－６和４．０５×１０－６，后裔遗传疾患的危险度均为４．０×１０－８，由此估计该次实践造成的人均寿命缩短时间为０．５２ｈ·人－１。利用江苏省结核病的患病率、死亡率、化疗治愈率估算出由此次实践带来的人均寿命延长时间为４５．８ｈ·人－１。     

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

: A rising prostate specific antigen (PSA) following treatment for adenocarcinoma of the prostate indicates eventual clinical failure, but the rate of rise can be quite different from patient to patient, as can the pattern of clinical failure. We sought to determine whether the rate of PSA rise could differentiate future local versus metastatistic failure.

: Two thousand six hundred sixty-seven PSA values from 400 patients treated with radiotherapy for localized adenocarcinoma of the prostate were analyzed with respect to PSA patterns and clinical outcome. Patients had received no hormonal therapy or prostate surgey and had ?4 PSA values post-treatment PSA rate of rise, determined by the slope of the natural log, was classified as gradual (< 0.69 log (ng/ml)/year, or doubling time (DT) > 1 year), moderate (0.69-1.4 log (ng/ml)/year, or DT 6 months-1 year), or rapid [>1.4 log (ng/ml)/year, or DT < 6 months].

: SIxty-one percent of patients had non-rising PSA following treatment; 25% of patients with rising PSA developed clinical failure, and 93% of patients with clinical failure had rising PSA. The rate of rise discerned different clinical failure patterns. Local failure occurred in 23% of patients with moderate rate of rise versus 7% with gradual rise (p = 0.0001). Metastatic disease developed in 46% of those with rapid versus 8% with moderate rise (p < 0.0001). By multivariate analysis, in addition to rate of rise, PSA nadir and rate of decline predicted local failure; those with post-treatment nadir of 1–4 ng/ml were five times more likely to experience local failure than nadir < 1 ng/ml (p = 0.0002). Rapid rate of rise was the most significant independent predictor of metastastic failure.

: The rate of PSA rise following definitive radiotherapy can predict clinical failure patterns, with a rapidly rising PSA indicating metastatic recurrence and moderately rising PSA local recurrence. This information could potentially dirent therapy; if the rise predicts metastatic failure hormonal therapy could be cosidereed, while aggressive salvage therapy may benefit subclinical local recurrence identified by a moderate rate of PSA rise.